The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.
Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy
Abstract
Addition of chemical tags on the DNA and modification of histone proteins impart a distinct feature on chromatin architecture. With the advancement in scientific research, the key players underlying these changes have been identified as epigenetic modifiers of the chromatin. Indeed, the plethora of enzymes catalyzing these modifications, portray the diversity of epigenetic space and the intricacy in regulating gene expression. These epigenetic players are categorized as writers: that introduce various chemical modifications on DNA and histones, readers: the specialized domain containing proteins that identify and interpret those modifications and erasers: the dedicated group of enzymes proficient in removing these chemical tags. Research over the past few decades has established that these epigenetic tools are associated with numerous disease conditions especially cancer. Besides, with the involvement of epigenetics in cancer, these enzymes and protein domains provide new targets for cancer drug development. This is certain from the volume of epigenetic research conducted in universities and R&D sector of pharmaceutical industry. Here we have highlighted the different types of epigenetic enzymes and protein domains with an emphasis on methylation and acetylation. This review also deals with the recent developments in small molecule inhibitors as potential anti-cancer drugs targeting the epigenetic space.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–240 of 240
Sirtuin Inhibition: Strategies, Inhibitors, and Therapeutic Potential
Jiang, Y., Liu, J., Chen, D., Yan, L., & Zheng, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.01.009 · Cited by 94
Readers of DNA methylation, the MBD family as potential therapeutic targets
Ginder, G. D., & Williams, D. C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.002 · Cited by 92
Zhou, X., & Mā, H. (2008) · BMC Evolutionary Biology · doi:10.1186/1471-2148-8-294 · Cited by 91
Zhu, Q., Huang, Y., Marton, L. J., Woster, P. M., Davidson, N. E., & Casero, R. A. (2011) · Amino Acids · doi:10.1007/s00726-011-1004-1 · Cited by 90
Wu, J., & Xu, W. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114905109 · Cited by 90
Selective recognition of acetylated histones by bromodomains in transcriptional co-activators
Hassan, A. H., Awad, S. M., Natour, Z. A., Othman, S., Mustafa, F., & Rizvi, T. A. (2007) · Biochemical Journal · doi:10.1042/bj20060907 · Cited by 88
ZBTB33 binds unmethylated regions of the genome associated with actively expressed genes
Blattler, A., Yao, L., Wang, Y., Ye, Z., Jin, V. X., & Farnham, P. J. (2013) · Epigenetics & Chromatin · doi:10.1186/1756-8935-6-13 · Cited by 82
Role of Jade-1 in the Histone Acetyltransferase (HAT) HBO1 Complex
Foy, R. L., Song, I. Y., Chitalia, V. C., Cohen, H. T., Saksouk, N., Cayrou, C., Vaziri, C., Côté, J., & Panchenko, M. V. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801407200 · Cited by 76
DOT1L Inhibition Sensitizes MLL-Rearranged AML to Chemotherapy
Liu, W., Deng, L., Song, Y., & Redell, M. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098270 · Cited by 76
Probing p300/CBP Associated Factor (PCAF)-Dependent Pathways with a Small Molecule Inhibitor
Modak, R., Basha, N. J., Bharathy, N., Maity, K., Mizar, P., Bhat, A. V., Vasudevan, M., Rao, V. K., Kok, W. K., Natesh, N., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb4000597 · Cited by 76
Wang, Y., Gu, M., Meng, F.-S., Jiao, W.-R., Zhou, X., Yao, H., & Ji, F. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4176 · Cited by 76
Müller, H. M., Fiegl, H., Goebel, G., Hubalek, M., Widschwendter, A., Müller‐Holzner, E., Marth, C., & Widschwendter, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601392 · Cited by 74
Williams, D. E., Dalisay, D. S., Li, F., Amphlett, J. T. M., Maneerat, W., Chavez, M. A. G., Wang, Y. A., Matainaho, T. K., Yu, W., Brown, P. J., et al. (2012) · Organic Letters · doi:10.1021/ol303416k · Cited by 72
Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2
Sweis, R. F., Wang, Z., Algire, M. A., Arrowsmith, C. H., Brown, P. J., Chiang, G. G., Guo, J. Q., Jakob, C. G., Kennedy, S., Li, F., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00124 · Cited by 71
Rajavelu, A., Tulyasheva, Z., Jaiswal, R., Jeltsch, A., & Kuhnert, N. (2011) · BMC Biochemistry · doi:10.1186/1471-2091-12-16 · Cited by 70
Jmjd6, a JmjC Dioxygenase with Many Interaction Partners and Pleiotropic Functions
Kwok, J., O’Shea, M. F., Hume, D. A., & Lengeling, A. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00032 · Cited by 70
Singh, M., Popowicz, G. M., Krajewski, M., & Holak, T. A. (2007) · ChemBioChem · doi:10.1002/cbic.200600562 · Cited by 69
MBD2 and MBD3: elusive functions and mechanisms
Menafra, R., & Stunnenberg, H. G. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00428 · Cited by 68
Competitive Binding of a Benzimidazole to the Histone-Binding Pocket of the Pygo PHD Finger
Miller, T. C. R., Rutherford, T. J., Birchall, K., Chugh, J., Fiedler, M., & Bienz, M. (2014) · ACS Chemical Biology · doi:10.1021/cb500585s · Cited by 67
Morris, J., Moseley, V. R., Cabang, A. B., Coleman, K., Wei, W., Garrett-Mayer, E. S., & Wargovich, M. J. (2016) · Oncotarget · doi:10.18632/oncotarget.9204 · Cited by 62
Koga, H., Matsui, S.-I., Hirota, T., Takebayashi, S., Okumura, K., & Saya, H. (1999) · Oncogene · doi:10.1038/sj.onc.1202732 · Cited by 60
The BAH domain of BAHD1 is a histone H3K27me3 reader
Zhao, D. Y., Zhang, X., Guan, H., Xiong, X., Shi, X., Deng, H., & Li, H. (2016) · Protein & Cell · doi:10.1007/s13238-016-0243-z · Cited by 60
Laget, S., Miotto, B., Chin, H. G., Estève, P., Roberts, R. J., Pradhan, S., & Defossez, P. (2014) · Epigenetics · doi:10.4161/epi.27695 · Cited by 58
Polybromo-1-bromodomains bind histone H3 at specific acetyl-lysine positions
Chandrasekaran, R., & Thompson, M. J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.01.193 · Cited by 58
Structure of the Chromo Barrel Domain from the MOF Acetyltransferase
Nielsen, P. R., Nietlispach, D., Buscaino, A., Warner, R. J., Akhtar, A., Murzin, A. G., Murzina, N. V., & Laue, E. D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501347200 · Cited by 57
Properties of the Type B Histone Acetyltransferase Hat1
Benson, L. J., Phillips, J. A., Gu, Y., Parthun, M. R., Hoffman, C. S., & Annunziato, A. T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607464200 · Cited by 57
Wu, S., Trievel, R. C., & Rice, J. C. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.06.025 · Cited by 57
Structural Insight into p53 Recognition by the 53BP1 Tandem Tudor Domain
Roy, S., Musselman, C. A., Kachirskaia, I., Hayashi, R., Glass, K. C., Nix, J. C., Gozani, O., Appella, E., & Kutateladze, T. G. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.024 · Cited by 53
Podcheko, A., Northcott, P. A., Bikopoulos, G. J., Lee, A., Bommareddi, S. R., Kushner, J. A., Farhang-Fallah, J., & Rozakis-Adcock, M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02409-06 · Cited by 53
Targeting DNA Methylation with Green Tea Catechins
Yiannakopoulou, E. C. (2015) · Pharmacology · doi:10.1159/000375503 · Cited by 52
Belinostat for the treatment of peripheral T-cell lymphomas
Jimeno, A., & McDermott, J. D. (2014) · Drugs of today · doi:10.1358/dot.2014.50.5.2138703 · Cited by 51
Chemical Inhibitors of Epigenetic Methyllysine Reader Proteins
Milosevich, N., & Hof, F. A. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b01073 · Cited by 50
Wang, T., Cui, H., MA, N., & Jiang, Y. (2013) · Oncology Letters · doi:10.3892/ol.2013.1400 · Cited by 49
Agarwal, P., & Jackson, S. P. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.009 · Cited by 40
Wiśnik, E., Płoszaj, T., & Robaszkiewicz, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-10307-z · Cited by 39
Identification of a peptide inhibitor for the histone methyltransferase WHSC1
Morrison, M. J., Boriack‐Sjodin, P. A., Swinger, K. K., Wigle, T. J., Sadalge, D., Kuntz, K. W., Scott, M. P., Janzen, W. P., Chesworth, R., Duncan, K. W., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197082 · Cited by 37
Structure–activity relationships of methyl-lysine reader antagonists
Herold, J. M., James, L. I., Korboukh, V. K., Gao, C., Coil, K. E., Bua, D. J., Norris, J. L., Kireev, D., Brown, P. J., Jin, J. J., et al. (2011) · MedChemComm · doi:10.1039/c1md00195g · Cited by 33
Trojer, P., & Reinberg, D. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5544 · Cited by 28
Harada, N., Takagi, T., Nakano, Y., Yamaji, R., & Inui, H. (2015) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2015.1025035 · Cited by 17
Crystal structure of chromo barrel domain of RBBP1
Lei, M., Feng, Y., Zhou, M., Yang, Y., Loppnau, P., Li, Y., Yang, Y. A., & Liu, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.016 · Cited by 4
Cited by
The timeline of epigenetic drug discovery: from reality to dreams
Ganesan, A., Arimondo, P. B., Rots, M. G., Jeronimo, C., & Berdasco, M. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0776-0 · Cited by 341
Epigenetics in hepatocellular carcinoma
Nagaraju, G. P., Dariya, B., Kasa, P., Peela, S., & El-Rayes, B. F. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.07.017 · Cited by 339
Cancer epigenetics: from laboratory studies and clinical trials to precision medicine
Yu, X., Zhao, H., Wang, R., Chen, Y., Ouyang, X., Li, W., Sun, Y., & Peng, A. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01803-z · Cited by 287
Liu, R., Wu, J., Guo, H., Yao, W., Li, S., Lu, Y., Jia, Y., Liang, X., Tang, J., & Zhang, H. (2023) · MedComm · doi:10.1002/mco2.292 · Cited by 264
The Regulation of Astrocytic Glutamate Transporters in Health and Neurodegenerative Diseases
Todd, A. C., & Hardingham, G. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249607 · Cited by 172
Metadata
- Authors
- Biswas, S., & Rao, C. M.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 837
- Pages
- 8-24
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2887245558
- Cited by
- 389
- References
- 240
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.